MARKET

VXRT

VXRT

VAXART
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.38
-0.67
-6.67%
Pre Market: 8.88 -0.5 -5.33% 06:05 01/27 EST
OPEN
10.72
PREV CLOSE
10.05
HIGH
10.81
LOW
8.66
VOLUME
19.21K
TURNOVER
--
52 WEEK HIGH
17.49
52 WEEK LOW
0.5600
MARKET CAP
1.03B
P/E (TTM)
-26.7923
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Vaxart Down 8%, Presents More Covid-19 Vaccine Data From Hamster Study
Dow Jones · 16h ago
Vaxart ticks lower despite COVID-19 vaccine shows benefit in lung inflammation in animal models
Investors seem to apparently reacting to not no overwhelming data from preclinical study evaluating Vaxart ([[VXRT]] -8.9%) oral vaccine candidate showing the candidate protected against lung inflammation in SARS-CoV-2 hamster
Seekingalpha · 18h ago
BRIEF-Vaxart Announces Additional Preclinical Covid-19 Oral Vaccine Data And Publication
reuters.com · 21h ago
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data, Publication; Says New Pre-Clinical Histology Data Shows Co's Oral Vaccine Protected Against Lung Inflammation In Hamster Models
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication New pre-clinical histology data show that Vaxart's oral vaccine protected against lung inflammation in hamster models   An
Benzinga · 21h ago
Vaxart Reports Positive Data From Study of COVID-19 Vaccine Candidate
MT Newswires · 1d ago
Accelerate Diagnostics and Vaxart are sharply up despite lofty short interest
In-vitro diagnostics company, Accelerate Diagnostics ([[AXDX]] +33.9%), and COVID-19 vaccine developer, Vaxart ([[VXRT]] +23.9%) operate in two entirely different industries in the healthcare sector.Given today’s steep climb in their stock
Seekingalpha · 1d ago
Vaxart, Inc.'s (NASDAQ:VXRT) Path To Profitability
Vaxart, Inc. ( NASDAQ:VXRT ) is possibly approaching a major achievement in its business, so we would like to shine...
Simply Wall St. · 5d ago
Vaxart falls despite Motley Fool pitch
Vaxart (VXRT) may have seen over a thirteen-fold rise in share price over the past 12-month period thanks to its COVID-19 vaccine development. That meteoric rise has not discouraged the
Seekingalpha · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VXRT. Analyze the recent business situations of VAXART through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VXRT stock price target is 17.67 with a high estimate of 20.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 148
Institutional Holdings: 37.73M
% Owned: 34.47%
Shares Outstanding: 109.47M
TypeInstitutionsShares
Increased
32
7.22M
New
74
14.35M
Decreased
18
4.37M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Director
Wouter Latour
Chief Executive Officer/Chief Financial Officer/Director
Andrei Floroiu
Chief Accounting Officer/Vice President/Controller
Margaret Echerd
Chief Scientific Officer
Sean Tucker
Other
David Taylor
Lead Director/Independent Director
Robert Yedid
Director
Steven Boyd
Director
Keith Maher
Independent Director
Todd Davis
Independent Director
Michael Finney
Director
I. Keith Maher
Independent Director
Anne VanLent
Independent Director
Bob Yedid
Independent Director
Karen Wilson
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
10/25/2012
Dividend USD 1.108
11/09/2012
About VXRT
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.